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Abstract
5-Fluorouracil (5-FU) is a commonly used drug for the treatment of malignant cancers. However, approximately 80% of
patients undergoing 5-FU treatment suffer from gastrointestinal mucositis. The aim of this report was to identify the drug
target for the 5-FU-induced intestinal mucositis. 5-FU-induced intestinal mucositis was established by intraperitoneally
administering mice with 100 mg/kg 5-FU. Network analysis of gene expression profile and bioluminescent imaging were
applied to identify the critical molecule associated with 5-FU-induced mucositis. Our data showed that 5-FU induced
inflammation in the small intestine, characterized by the increased intestinal wall thickness and crypt length, the decreased
villus height, and the increased myeloperoxidase activity in tissues and proinflammatory cytokine production in sera.
Network analysis of 5-FU-affected genes by transcriptomic tool showed that the expression of genes was regulated by
nuclear factor-kB (NF-kB), and NF-kB was the central molecule in the 5-FU-regulated biological network. NF-kB activity was
activated by 5-FU in the intestine, which was judged by in vivo bioluminescence imaging and immunohistochemical
staining. However, 5-aminosalicylic acid (5-ASA) inhibited 5-FU-induced NF-kB activation and proinflammatory cytokine
production. Moreover, 5-FU-induced histological changes were improved by 5-ASA. In conclusion, our findings suggested
that NF-kB was the critical molecule associated with the pathogenesis of 5-FU-induced mucositis, and inhibition of NF-kB
activity ameliorated the mucosal damage caused by 5-FU.
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Introduction
5-Fluorouracil (5-FU) is the most commonly used chemotherapy
drug in the clinical oncologic practice. It is widely used for the
treatment of various cancers, including gastrointestinal cancer,
breast cancer, and head and neck cancer [1,2]. Clinical evidence
from patients undergoing 5-FU therapy indicates that personal
response to 5-FU is different. Some people display slight side
effects, while others suffer from severe adverse effects that lead to
the discontinuance of cancer therapy. The commonly side effects
of 5-FU include myelosuppression, dermatitis, cardiac toxicity,
diarrhea, and mucositis [1,3]. Among these adverse effects,
gastrointestinal mucositis is a major complication that occurs in
approximately 80% of patients receiving 5-FU and results in
abdominal bloating as well as vomiting and diarrhea [4].
Mucositis usually appears along the entire gastrointestinal tract
from mouth to anus and causes general debility. Mucositis of the
intestine is characterized by increased crypt apoptosis and villus
atrophy, leaving the mucosal tissue open to ulceration and
infection [5–7]. Several factors or genes contributing to the 5-
FU-induced mucositis have been studied. For examples, increased
apoptosis and decreased cellularity by 5-FU cause the histological
change in the intestine [8]. The formation of reactive oxygen
species (ROS) and the production of proinflammatory cytokines,
such as interleukin-1b (IL-1b), IL-6 and tumor necrosis factor-a
(TNF-a), lead to the mucosal damage [9–11]. Additionally, the
production of platelet-activating factor (PAF) participates in the
pathogenesis of mucositis [12]. Although several genes have been
suggested to be involved in the 5-FU-induced intestinal mucositis,
the key molecules, especially the upstream transcription factors
that regulate the downstream genes associated with the pathogen-
esis of mucositis are still uncertain. Moreover, better compounds
targeting to the mechanism of mucosal injury remain to be
developed for the treatment of mucositis.
Nuclear factor-kB (NF-kB) is an inducible transcription factor
that consists of heterodimers of RelA (p65), c-Rel, RelB, p50/NF-
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kB1, and p52/NF-kB2. NF-kB is a central coordinator of innate
and adaptive immune responses. It is also involved in the
regulation of inflammatory cytokine production and inflammation
[13,14]. When cells are exposed to the inflammatory and stress
stimulators, NF-kB activates the downstream genes, including
cytokine, cytokine receptor and cyclooxygenase genes, resulting in
the inflammatory process [15,16]. Accordingly, controlling NF-kB
activation may be a potent strategy for the treatment of inflammation.
In this study, we analyzed the mechanism of 5-FU-induced
intestinal damage by transcriptomic analysis and bioluminescent
imaging. Our findings demonstrated that NF-kB was the likely key
molecule involved in the 5-FU-induced mucositis and inhibition of
NF-kB activity by 5-aminosalicylic acid (5-ASA) improved the
mucosal damage caused by 5-FU.
Materials and Methods
Animal experiments
Mouse experiments were conducted under ethics approval from
China Medical University Animal Ethics Committee (Permit
Number: 97-28-N). Transgenic mice carrying the NF-kB-driven
luciferase gene were constructed as described previously [17].
BALB/c mice were purchased from National Laboratory Animal
Center (Taipei, Taiwan).
The 5-FU-induced mucositis model was established as described
previously [7]. Male mice (6 to 8 weeks old) were injected
intraperitoneally with phosphate-buffered saline (PBS) (137 mM
NaCl, 1.4 mMKH2PO4, 4.3 mMNa2HPO4, 2.7 mMKCl, pH 7.2)
or 5-FU (100 mg/kg) (Sigma, St Louis, MO, USA). For 5-ASA
treatment, mice were orally administered with 5-ASA (130 mM/kg)
for two consecutive days before intraperitoneal administration of 5-
FU and two consecutive days after 5-Fu administration. Mice were
imaged for the luciferase activity or sacrificed for histological and
immunohistochemical evaluations at indicated periods.
Histological analysis
Mice intestines were fixed in 10% phosphate-buffered formalin
for 2 d and dehydrated in a series of graded alcohols (50%, 70%,
and 95%) for 30 min each. Samples were then embedded in
paraffin, cut into 5-mm sections, stained with hematoxylin and
eosin (H&E), and subjected to blinded histological assessment.
Villus height was measured from the baseline to the villus tip.
Crypt length was measured from the baseline to the submucosa.
The thickness of intestinal wall was measured from the submucosa
to the serosa. Three independent measurements from 3 different
longitudinal sections per mouse were made.
Microarray analysis
Total RNA was extracted from jejunum using RNeasy Mini kit
(Qiagen, Valencia, CA, USA). Total RNA was quantified and
evaluated as described previously [18]. Microarray analysis was
performed as described previously [18–20]. Briefly, fluorescent-
labeled RNA targets were prepared from 5 mg of total RNA using
MessageAmpTM aRNA kit (Ambion, Austin, TX, USA) and Cy5
dye (Amersham Pharmacia, Piscataway, NJ, USA). Fluorescent
targets were hybridized to the Mouse Whole Genome OneAr-
rayTM (Phalanx Biotech Group, Hsinchu, Taiwan) and scanned by
an Axon 4000 scanner (Molecular Devices, Sunnyvale, CA, USA).
Three replicates from three independent mice were performed.
The Cy5 fluorescent intensity of each spot was analyzed by
genepix 4.1 software (Molecular Devices). The signal intensity of
each spot was corrected by subtracting background signals in the
surroundings. We filtered out spots that signal-to-noise ratio was
less than 0 or control probes. Spots that passed these criteria were
normalized by R program [21]. The fold changes of genes were
calculated by dividing the normalized signal intensities of genes in
5-FU-treated mice by those in PBS-treated mice. Genes with fold
changes $2 or #22 were selected and used as the input genes for
the generation of biological network using Transcription Regula-
tion algorithm in MetaCoreTM Analytical suite (GeneGo Inc., St.
Joseph, MI, USA). All microarray data are MIAME compliant and
the raw data have been deposited in a MIAME compliant database
(Gene Expression Omnibus, accession number GSE28873).
In vivo and ex vivo imaging of luciferase activity
For in vivo imaging, mice were anesthetized with isoflurane and
injected intraperitoneally with 150 mg/kg D-luciferin. Five minutes
later, mice were placed facing up in the chamber and imaged for
1 min with the camera set at the highest sensitivity by IVIS Imaging
SystemH 200 Series (Xenogen, Hopkinton, MA, USA). Photons
emitted from the whole bodies were quantified using Living ImageH
software (Xenogen). Signal intensity was quantified as the sum of all
detected photon counts from the whole body and presented as
photon/sec. For ex vivo imaging, mice were anesthetized and
injected with luciferin intraperitoneally. Five minutes later, mice
were sacrificed and tissues were rapidly removed. Tissues were
placed in the IVIS system and imaged with the same setting used for
in vivo studies. Signal intensity was quantified as the sum of all
detected photon counts per second within the region of interest after
subtracting the background luminescence and presented as photon/
sec/cm2/steradian (photon/sec/cm2/sr).
Immunohistochemical staining
Sections of 5 mm were deparaffinized in xylene and rehydrated
in graded alcohol. Endogenous peroxidase was quenched with 3%
hydrogen peroxide in methanol for 15 min and the nonspecific
binding was blocked with 1% bovine serum albumin at room
temperature for 1 h. Sections were incubated with mouse
monoclonal antibody against NF-kB p65 subunit (Chemicon,
Temecula, CA, USA) or rabbit polyclonal antibody against IL-1b
(Santa Cruz, CA, USA) or TNF-a (AbcamH, Cambridge, UK) at
1:50 dilution overnight at 4uC and then incubated with
biotinylated secondary antibody (Zymed Laboratories, Carlsbad,
CA, USA) at room temperature for 20 min. Finally, slides were
incubated with avidin-biotin complex reagent and stained with
3,39-diaminobenzidine according to manufacturer’s protocol
(HistostainsH-Plus, Zymed Laboratories).
Cytokine enzyme-linked immunosorbent assay (ELISA)
IL-1b and TNF-a in sera were quantified by ELISA with
QuantikineH mouse immunoassay kits (R&D Systems, Minneap-
olis, MN, USA). Briefly, sera were added to wells, which were
coated with monoclonal antibody against IL-1b or TNF-a. After
five washes, the biotinylated antibody against IL-1b or TNF-a, the
peroxidase-conjugated avidin, and the chromogenic substrates
were sequentially added to each well. The absorbance was read at
450 nm in an ELISA reader.
Myeloperoxidase (MPO) assay
MPO activities in the jejunum were quantified with MPO
colorimetric activity assay kit (BioVision, Mountain View, CA,
USA). Briefly, the frozen tissues were homogenized and centri-
fuged to remove insoluble materials. Supernatants were collected,
mixed with MPO assay buffer and MPO substrate, incubated at
room temperature for 1 h, and then mixed with tetramethylben-
zidine probe. The absorbance was read at 412 nm in an ELISA
reader.
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Statistical analysis
Data were presented as mean 6 standard error. Student’s t-test
was used for comparisons between two experiments. A value of
p,0.05 was considered statistically significant.
Results
5-FU induced intestinal mucositis
Chemotherapy-induced diarrhea occurs in approximately 80%
of patients treated with 5-FU. Previous studies have shown that 5-
FU kills progenitor cells in the crypts of Lieberku¨hn and the bases
of villi, leading to the breakdown of mucosal barrier [22].
Moreover, 5-FU administration results in increased apoptosis and
decreased cellularity in the small intestine [8]. We therefore
intraperitoneally administered mice with 5-FU and the histological
changes in the small intestine were evaluated 2 days later. In
comparison with mock, 5-FU caused mucosal damage in the small
intestine (Figure 1). 5-FU decreased the height of villi and caused
the blunting and fusion of villi. Moreover, 5-FU led to the
intestinal inflammation, characterized by the infiltration of
immune cells and the accumulation of fluid, and subsequently
increased the length of crypts. 5-FU also increased the thickness of
intestinal wall. These findings indicated that intraperitoneal
administration of 5-FU caused the mucosal damage and
inflammation in the small intestine.
NF-kB was the central molecule in the 5-FU-affected
gene expression network
We further elucidated the mechanism of 5-FU-induced
intestinal mucositis by transcriptomic analysis. In a total of
29,922 genes, 1,614 genes were upregulated and 1,574 genes were
downregulated by 2 fold by 5-FU. These genes were selected for
the generation of biological network using Transcription Regula-
tion algorithm in MetaCore. As shown in Figure 2, 5-FU-affected
genes were directly connected to the NF-kB, suggesting that
expressions of 5-FU-affected genes were regulated by NF-kB. The
expression levels of genes in the network are shown in Table S1.
Furthermore, NF-kB seemed to be the central molecule of the
network. These findings suggested that NF-kB was the likely key
molecule involved in the 5-FU-induced intestinal mucositis.
5-FU evoked the NF-kB activity judged by in vivo and ex
vivo imaging
Transcriptomic analysis showed that NF-kB was the central
molecule in the 5-FU-affected gene expression network. We
therefore performed in vivo and ex vivo imaging to elucidate the NF-
kB activity in mice following 5-FU administration. Transgenic
mice carrying the luciferase gene driven by a promoter with five
NF-kB responsive elements were used here. The luciferase activity
reflected the NF-kB trans-activity.
Transgenic mice were intraperitoneally given with PBS or 5-
FU, and the bioluminescent imaging was performed on 0, 1, 2, 5,
7, and 14 d. Figure 3A shows that a maximal induction of NF-kB
activity was observed on 2 d following 5-FU administration and ex
vivo imaging was therefore performed on 2 d. As shown in
Figure 3B and Figure 3C, 5-FU slightly affected the NF-kB
activities in lung, liver, spleen, and stomach, while 5-FU
significantly activated the NF-kB activity in the small intestine
by 2.2-fold. These findings indicated that 5-FU evoked the whole
body NF-kB activity on 2 d and induced the NF-kB activation in
the small intestine. Moreover, 5-FU-induced intestinal mucositis
could be assessed by NF-kB bioluminescent imaging.
5-FU-induced NF-kB activity was inhibited by 5-ASA
5-ASA is an anti-inflammatory drug that has been used for the
treatment of ulcerative colitis for decades [23]. Activation of NF-
kB in biopsies of ulcerative colitis is suppressed by 5-ASA,
suggesting that 5-ASA is a potent inhibitor of NF-kB activation in
vivo [23]. We therefore evaluated whether 5-ASA inhibited 5-FU-
induced NF-kB activation and subsequently ameliorated the 5-
FU-caused mucositis. Transgenic mice were administered with 5-
FU and/or 5-ASA and imaged 2 days later. 5-FU induced the NF-
kB activity in the small intestine, which was in agreement with
aforementioned findings (Figure 3D). However, 5-ASA signifi-
cantly reduced the 5-FU-induced NF-kB activity, with a 42%
reduction of bioluminescent intensity. Immunohistochemical
staining with antibody against NF-kB p65 subunit revealed that,
in comparison with mock, there were many brown p65-reactive
cells in the crypts and villi of 5-FU-treated intestine (Figure 4A).
However, 5-ASA reduced the number of brown p65-reactive cells
in the intestine. These findings indicated that 5-FU evoked the
NF-kB activity, while 5-ASA inhibited 5-FU-induced NF-kB
activity in the intestine.
Inhibition of NF-kB activity ameliorated the 5-FU-induced
mucositis in the small intestine
We further tested whether the inhibition of 5-FU-induced NF-
kB activity by 5-ASA improved the 5-FU-caused intestinal
mucositis. Histological examination of the small intestine following
5-FU and/or 5-ASA treatment showed that 5-FU increased the
thickness of intestinal wall and the length of crypt, while 5-ASA
significantly decreased 5-FU-caused histological changes (Figure 5).
5-FU also decreased the height of villus, while 5-ASA slightly
Figure 1. Histological examination of the small intestine
following 5-FU administration. BALB/c mice were intraperitoneally
administered with PBS (mock) or 5-FU and sacrificed 2 days later. (A)
Microscopic features of the jejunum. Sections were stained with H&E
and observed using light microscopy. Magnification 1006. Photos are
representative images. (B) Intestinal morphometry of intestinal wall
thickness, crypt length, and villus height. Six mice in each group were
sacrificed for the morphometry analysis. Three intestinal walls, crypts,
and villi in 3 longitudinal sections per mouse were counted. Results are
expressed as relative length, which is presented as a comparison with
the length or thickness relative to mock. Values are mean 6 standard
error. **p,0.01, ***p,0.001, compared with mock.
doi:10.1371/journal.pone.0031808.g001
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increased it. In addition to the histological changes, MPO activities
in the intestine were induced by 5-FU and suppressed by 5-ASA,
also indicating that 5-FU induced intestinal inflammation, while 5-
ASA suppressed 5-FU-induced inflammation (Figure 4B). The
levels of IL-1b and TNF-a in the tissues and sera were evaluated
by immunohistochemical staining and cytokine ELISA, respec-
tively. As shown in Figures 4A and 4C, 5-FU induced the
immunomarcation for IL-1b and TNF-a in the tissues and
increased the levels of IL-1b and TNF-a in sera, while 5-ASA
suppressed 5-FU-induced IL-1b and TNF-a production in the
tissues and sera. These findings suggested that 5-FU induced
intestinal mucositis via NF-kB activity. Moreover, inhibition of
NF-kB activity decreased the 5-FU-induced TNF-a production
and subsequently improved the 5-FU-caused mucosal damage in
the small intestine.
Discussion
5-FU is a commonly used chemotherapy drug for the treatment
of malignant tumors. It kills tumor cells through interfering DNA
synthesis and affecting protein synthesis [2]. Approximately 80%
of patients undergoing 5-FU therapy suffer from a range of
symptoms, including mucositis and diarrhea. Gastrointestinal
mucositis is frequently associated with pain and increased risk of
infection. It leads to impaired quality of life in patients. Moreover,
patients may no longer be able to continue cancer therapy in cases
of severe mucositis [24]. Therefore, developing better therapeutic
drug targeting to the mechanisms of mucosal damage is awaited.
Mechanisms involved in the pathogenesis of mucositis are very
complex. Apoptosis, hypoproliferation, and inflammation contrib-
ute to the mucosal injury [9]. It has been reported that the
Figure 2. Network analysis of 5-FU-affected genes in the small intestine. Upregulated genes are marked with red circles/disks.
Downregulated genes are marked with blue circles/disks. Cyan lines indicate the fragments of canonical pathways.
doi:10.1371/journal.pone.0031808.g002
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expression of proinflammatory cytokines, such as IL-6 and TNF-a,
in the small intestine and colon of rodents after chemotherapy is
significantly increased [7,25]. IL-1 and IL-1 receptor antagonist
are produced locally in the intestinal mucosa, and their expressions
are increased in inflammatory mucosa [26,27]. Moreover, IL-1b
plays a critical role in the genesis and development of intestinal
mucositis after chemotherapy, and this type of effect is caused by
inducing crypt cell apoptosis [11]. In addition to the proin-
flammatory cytokines, ROS generated by inducible nitric oxide
synthase (iNOS) and cyclooxygenase-2 (COX-2) lead to the
mucosal injury. Increased iNOS and COX-2 activity in the 5-FU-
and radiation-induced mucositis, suggesting the important role of
ROS in the pathogenesis of oral mucositis [9,10]. Recently, the
role of PAF in 5-FU-induced intestinal mucositis has been
suggested using knockout animals and an antagonist of PAF
receptor [12]. Because the expressions of proinflammatory
cytokines, iNOS, COX-2, and PAF are regulated by various
transcription factors, we applied transcriptomic analysis to find the
upstream transcription factors that regulate the downstream gene
expression and lead to mucosal injury.
Transcriptomic analysis by DNA microarray tool is a popular
research and screening tool for differentially expressed genes.
Microarray-based gene expression patterns have been used to
predict the clinical outcome and prognosis of patients undergoing
5-FU therapy [28-30]. It has also been applied to predict the
therapeutic efficacy of 5-FU and to identify the biomarkers in
various cancers [31,32]. We used microarray tool for the first time
to identify the key molecule involved in the 5-FU-caused intestinal
injury in this study. The expression levels of IL-6, TNF-a, and IL-
1b were increased, with fold changes of 2.28, 3.37, and 6.77,
respectively (data not shown). These data were in agreement with
previous reports. Further network analysis using Transcription
Regulation algorithm indicated that the expression of 5-FU-
affected genes was regulated by NF-kB, and NF-kB was the
central molecule in the biological network. These findings
suggested that NF-kB was the upstream key molecule that
regulated the expression of downstream genes and led to the
mucositis of intestine.
NF-kB is a central coordinator of innate and adaptive immune
responses. NF-kB has also been linked to the control of cell
Figure 3. NF-kB-dependent bioluminescence in living mice and individual organs following 5-FU administration. (A) In vivo imaging.
Transgenic mice were injected intraperitoneally with PBS or 5-FU and imaged at indicated periods. Results are expressed as relative intensity, which is
presented as the comparison with the NF-kB-dependent bioluminescent signal relative to mock. Values are mean 6 standard error (n=6 per group).
*p,0.05, compared with mock. (B) Ex vivo imaging. Transgenic mice were injected intraperitoneally with PBS (mock) or 5-FU. Two days later, mice were
sacrificed and organs were subjected to image. The color overlay on the image represents the photon/sec emitted from the organs, as indicated by the
color scale. Photos are representative images (n=6 per group). (C) Quantification of photon emission from the organs. Values are mean6 standard error
(n=6 per group). **p,0.01, compared with mock. (D) NF-kB-dependent bioluminescence in the intestine following 5-FU and/or 5-ASA administration.
Transgenic mice were administered with 5-FU and/or 5-ASA and imaged 2 days later. The color overlay on the image represents the photon/sec emitted
from the intestine, as indicated by the color scale. Photos are representative images (n=6 per group). Quantification of photon emission from the
intestine was shown on the top. Values are mean 6 standard error. *p,0.05, compared with mock. #p,0.05, compared with 5-FU treatment.
doi:10.1371/journal.pone.0031808.g003
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growth, apoptosis, and cell cycle [33]. Previous reports have
implicated the NF-kB in the pathogenesis of several inflammatory
diseases, such as local joint inflammation, glomerulonephritis, and
inflammatory bowel diseases [34-36]. NF-kB activation is also
found in biopsy tissues in cancer patients treated with radiation
and several chemotherapeutic drugs, except 5-FU [6,37]. As a
consequence of the gene upregulation by the initial activation of
NF-kB, a broad range of biological active proteins accumulate and
target to the submucosa tissue in the gastrointestinal tract. NF-kB
activation induced by anti-neoplastic agents and radiation is
therefore though to elicit the inflammatory and apoptotic
responses that lead to the mucosal injury. In this study, we found
that NF-kB was the critical molecule that regulated the expression
of 5-FU-affected genes, and NF-kB activity was induced by 5-FU
in the intestine. In contrast, other studies indicated that 5-FU
administration inhibits NF-kB activation in vitro. Aota et al [38]
and Azuma et al [39] reported that 5-FU suppresses NF-kB
activity via the inhibition of IkB kinase activity and subsequently
induces apoptosis in human salivary gland cancer cells. Contra-
dictory effects of NF-kB activation on normal and cancer cells
have been reported [40]. Activation of NF-kB can be either pro-
apoptotic or anti-apoptotic, depending on the target cells.
Therefore, it is possible that NF-kB activated by 5-FU results in
apoptotic signals and proinflammatory cytokine production in
normal mucosal tissue and sequentially contributed to the injury of
gastrointestinal tract.
Bioluminescent imaging was applied to evaluate the NF-kB
activity after 5-FU administration. Transgenic mice carrying the
luciferase gene under the control of NF-kB-responsive element were
constructed previously, and the bioluminescent signal correlated
with NF-kB activity indicated that bioluminescent intensity
represents NF-kB activity in vivo [17,36]. Oral administration of 5-
ASA has been used for decades for the treatment of inflammatory
bowel disease [23]. 5-ASA is an anti-inflammatory drug that inhibits
NF-kB activation and suppressed the inflammatory response [23].
In this study, we also found that 5-ASA decreased 5-FU-induced
NF-kB activity and immunomarcation for IL-1b and TNF-a in the
intestine. The histological changes of mucositis have also been
improved. These findings suggested that inhibition of NF-kB
activity might result in the suppression of inflammation and the
sequential amelioration of mucositis in the intestine.
In conclusion, our findings suggested that NF-kB was the
critical molecule involved in the 5-FU-caused mucosal injury,
while inhibition of NF-kB activity suppressed the 5-FU-induced
inflammation and sequentially improved the 5-FU-induced
mucosal damage. These findings suggested that NF-kB was the
potent target for the development of drugs for the treatment of 5-
FU-induced mucositis.
Figure 4. Immunohistochemical staining and MPO activity of jejunum and cytokine ELISA of sera following 5-FU and/or 5-ASA
administration. Transgenic mice were administered with 5-FU and/or 5-ASA and sacrificed 2 days later. (A) Sections were stained by
immunohistochemistry using antibody against NF-kB, IL-1b, or TNF-a. Magnification 1006. Photos are representative images (n= 6 per group). (B)
MPO activity assay. Frozen jejunum was homogenized and MPO activity in the tissue was analyzed. Values are mean 6 standard error. *p,0.05,
compared with mock. (C) Cytokine ELISA. The levels of IL-1b and TNF-a were analyzed by cytokine ELISA. Values are mean6 standard error. *p,0.05,
***p,0.001, compared with mock. ###p,0.001, compared with 5-FU treatment.
doi:10.1371/journal.pone.0031808.g004
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